Tesamorelin

Mechanism (as reported)

A review reported that tesamorelin is a synthetic analogue of growth hormone-releasing hormone (growth hormone-releasing factor) that stimulates synthesis and release of endogenous growth hormone. (PMIDs: 22050344, 21668043) Another orthopaedics-focused review described growth hormone secretagogues including tesamorelin as activating IGF-1 signaling and satellite cell repair in the context of musculoskeletal relevance. (PMID: 41490200)

Key findings (each cites a source)

• Tesamorelin is described as the only FDA-approved therapy for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy. (PMIDs: 21283099, 22050344, 21668043, 38905488) [PMID 21283099, 22050344, 21668043, 38905488]
• Orthopaedic evidence reviews reported that tesamorelin has no supporting orthopaedic evidence. (PMID: 41476424) [PMID 41476424]
• A randomized double-blind trial analysis in people with HIV on integrase inhibitor–based regimens reported tesamorelin produced significant declines in visceral fat, hepatic fat, and trunk-to-appendicular fat ratio compared with placebo at 12 months, with similar frequency of adverse events between groups and no exacerbation of glycemic control as reported by the analysis. (PMID: 38905488) [PMID 38905488]
• A review of tesamorelin in HIV-associated lipodystrophy described two 26-week, well-designed clinical trials as reporting that tesamorelin reduced visceral adipose tissue, without affecting subcutaneous adipose tissue to a clinically significant extent; it further described that continued therapy maintained VAT reduction through week 52, while discontinuation resulted in VAT reaccumulation. (PMIDs: 22050344, 21668043) [PMID 22050344, 21668043]
• Reviews in HIV-associated lipodystrophy described tesamorelin as generally well tolerated over 26 weeks, with treatment-emergent serious adverse events occurring in <4% of patients, and most serious events described as injection-site reactions or events known to be associated with growth hormone therapy (e.g., arthralgia, headache, peripheral edema). (PMIDs: 22050344, 21668043) [PMID 22050344, 21668043]
• An orthopaedics/sports-medicine review described peptide therapy as often having limited or missing clinical evidence and stated that information regarding indications, dosing, frequency, and duration remains unknown, including in the context of peptides such as tesamorelin. (PMID: 41476424) [PMID 41476424]
• An orthopaedics-focused review described growth hormone secretagogues (including tesamorelin) as activating IGF-1 signaling and satellite cell repair, while also emphasizing the lack of clinical trials. (PMID: 41490200) [PMID 41490200]
• A narrative review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance included tesamorelin among prominent peptides marketed to patients and stated that rigorous human safety data are scarce for many unapproved peptides. (PMID: 41966639) [PMID 41966639]